Crossmark

Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty

Published Online: 2021-05-01

Published Print: 2022-02

Authors

Kochar, Bharati D.

Cai, Winston

Ananthakrishnan, Ashwin N. https://orcid.org/0000-0002-9436-1821
License Information

Text and Data Mining valid from 2021-05-01

Version of Record valid from 2021-05-01
More Information

Article History

Received: 22 January 2021

Accepted: 2 March 2021

First Online: 1 May 2021

Declaration

:

: BK: Advisory board for Pfizer. WC: No conflicts of interest. ANA: Scientific Advisory Board for Ikena therapeutics and Gilead.

Document is current